8-K filing — Turn Therapeutics Inc. (TTRX)
Filed: 2026-09-10 AccNo: 0001213900-26-098584 Size: 213 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
8-K filing — Turn Therapeutics Inc. (TTRX)
Filed: 2026-09-09 AccNo: 0001213900-26-098224 Size: 215 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Turn Therapeutics Publishes Peer-Reviewed Research Of GX-03 In Life.
In-vivo study showed GX-03 reduced IL-36, a key early driver of the inflammatory cascade, by approximately 50%, IL-31, a major driver of itch, by nearly 68%, and IL-4, an important inflammatory cytokine, by 16.7%
Turn Therapeutics Q2 EPS $(0.20) Misses $(0.02) Estimate
Why Is Turn Therapeutics Stock Trading Higher Today?
Turn Therapeutics expanded its GX-03 Phase 2 trial after interim data supported efficacy across a broader atopic dermatitis population.